Home / Pharmaceuticals / Chemotherapy Induced Nausea And Vomiting Treatment Market By Drug Class (Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine, Others) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Chemotherapy Induced Nausea And Vomiting Treatment Market By Drug Class (Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine, Others) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Published: Aug 2018 | Report Code: 59261-08-18

Industry Outlook

The chemotherapy induced nausea and vomiting treatment market is set to reach US$ 3,626.1 Mn by 2026 from US$ 2,057.4 Mn in 2017 showcasing progressive growth at a compound annual growth rate (CAGR) of 6.5% during the forecast period from 2018 to 2026. As per the latest statistics provided by the National Cancer Institute in 2018 approximately 1,735,350 new cancer cases will be reported with an estimation of 609,640 people dying with cancer. Technological advancement in the diagnostic kits have resulted in early cancer diagnosis which helps the physician to enroll the patient on chemotherapy treatment immediately. It is important to understand that 90% patient receiving chemotherapy suffer with nausea and vomiting.

There has been a shift in the treatment regimen, earlier dopamine antagonist in combination with corticosteroid were prescribed as antiemetic agents, which have been replaced by drug combination of serotonin receptor antagonist and NK1 receptor antagonist. Rising prevalence of cancer and growing popularity of chemotherapy as treatment option is responsible for the dominance of North America in CINV treatment market. Developing healthcare infrastructure and competition exerted by local generic drug manufacturers stimulate the CINV market growth in Asia Pacific.

Market Synopsis

Chemotherapy Induced Nausea And Vomiting Treatment Market

Excellent pharmacokinetic properties to boost the sale of NK1 receptor antagonist during the forecast period

Serotonin receptor antagonist are leading the drug class market for chemotherapy induced nausea and vomiting treatment on account of its excellent antiemetic activity in cancer patients suffering with acute nausea. Drugs such as palonosetron, granisetron and dolasetron are available as oral, parenteral and transdermal patches, catering the need of patients belonging to all age groups. Multiple studies conducted in the clinical trials have suggested the combined therapy of dopamine antagonist with benzodiazepine or corticosteroid to be effective in treating the patients suffering with refractory CINV. NK1 receptor antagonist have shown excellent clinical outcomes in the treatment of delayed nausea with outstanding pharmacokinetic properties. They are prescribed in combination with 5HT3 receptor antagonist e.g. Alkynzeo (Helsinn Healthcare) and is set to register tremendous growth during the forecast period.

Chemotherapy Induced Nausea And Vomiting Treatment Market

Increasing number of patients seeking chemotherapy to drive the CINV treatment market in North America

North America is currently leading the chemotherapy induced nausea and vomiting treatment market with 38% regional share. Rising prevalence of patients suffering with cancer, growing popularity of chemotherapy as treatment option among the patient population drives the CINV market in North America. Major players such as Sanofi-Aventis and Helsinn healthcare are striving to manufacture effective antiemetic drugs to treat CINV in North America. Existence of well-developed healthcare infrastructure, and adherence to treatment guidelines steers the CINV market in Europe. Competition exerted by the local players manufacturing generic drugs and supportive regulatory environment propel the CINV market growth in Asia Pacific region. Latin America and Middle East and Africa serve as lucrative market due to rising awareness of chemotherapy induced nausea and vomiting in healthcare professionals and rise in per capita income.

Chemotherapy Induced Nausea And Vomiting Treatment Market

Historical & Forecast Period

2016 – Historical Year

2017 – Base Year

2018-2026 – Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Chemotherapy Induced Nausea And Vomiting Treatment Market

Report Scope by Segments

Quantitative analysis for the report chemotherapy induced nausea and vomiting treatment market is postulated on the basis of latest market trends. The market is further segmented as drug class and geography.

By Drug Class (2016–2026; US$ Mn)

  • Serotonin Receptor Antagonist
    • Ondansetron
    • Granisetron
    • Dolasetron
    • Palonosetron
  • Neurokinin NK1 Receptor Antagonist
    • Aprepitant
    • Casopitant
    • Netupitant
  • Dopamine Antagonist
    • Metoclopramide
    • Prochlorperazine
  • Benzodiazepine
    • Lorazepam\
    • Others (Corticosteroids, Cannabinoids)

Geography Segment (2016–2026; US$ Mn)

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • Japan
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • GCC
    • Rest of Middle East and Africa

Latest market trends and quantitative analysis are performed to understand the market dynamics existing in the chemotherapy induced nausea and vomiting treatment market. Vital information regarding the inorganic business strategies such as mergers and collaboration between pharmaceutical players are highlighted in this report. In the product portfolio section quick insight regarding the diverse brands in different drug combinations is obtained. The major players dominating the chemotherapy induced nausea and vomiting treatment market are Baxter Pharmaceuticals, Eisai, Inc., Helsinn Healthcare, GlaxoSmithkline, Plc, Merck & Co. Inc., ProStrakan, Inc., Pfizer, Inc., Sanofi-Aventis, Solvay Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd.

Key questions answered in this report

  • Who are the leading players in the chemotherapy induced nausea and vomiting treatment market?
  • What will be the performance of the CINV market during the forecast period from 2018 to 2026?
  • What are the latest market trends existing in the CINV treatment market?
  • What are the drivers and challenges faced by the CINV treatment market?
  • What is the pathophysiology that triggers the chemotherapy induced nausea and vomiting?
  • What are the treatment guidelines adopted by the healthcare professionals throughout the globe?
  • Which is the leading and fastest growing drug class segment for CINV treatment market?
  • Which is the leading and fastest growing regional segment for CINV treatment market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Chemotherapy Induced Nausea and Vomiting Treatment Market Portraiture
2.2. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Class, 2017 (US$ Mn)
2.3. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Geography, 2017 (US$ Mn)

Chapter 3. Chemotherapy Induced Nausea and Vomiting Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Key Players, 2017

Chapter 4. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class
4.1. Overview
4.2. Serotonin Receptor Antagonist
4.2.1. Ondansetron
4.2.2. Granisetron
4.2.3. Dolasetron
4.2.4. Palonosetron
4.3. Neurokinin NK1 Receptor Antagonist
4.3.1. Aprepitant
4.3.2. Casopitant
4.3.3. Netupitant
4.4. Dopamine Antagonist
4.4.1. Metoclopramide
4.4.2. Prochlorperazine
4.5. Benzodiazepine
4.5.1. Lorazepam
4.6. Others (Corticosteroids, Cannabinoids)

Chapter 5. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Geography
5.1. Overview
5.2. North America Chemotherapy Induced Nausea and Vomiting Treatment Market Analysis, 2016 – 2026
5.2.1. North America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Chemotherapy Induced Nausea and Vomiting Treatment Market Analysis, 2016 – 2026
5.3.1. Europe Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market Analysis, 2016 – 2026
5.4.1. Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America Chemotherapy Induced Nausea and Vomiting Treatment Market Analysis, 2016 – 2026
5.5.1. Latin America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa Chemotherapy Induced Nausea and Vomiting Treatment Market Analysis, 2016 – 2026
5.6.1. MEA Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. MEA Chemotherapy Induced Nausea and Vomiting Treatment Market, by Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Baxter Pharmaceuticals
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Eisai, Inc.
6.3. Helsinn Healthcare
6.4. GlaxoSmithkline, Plc
6.5. Merck & Co. Inc.
6.6. ProStrakan, Inc.
6.7. Pfizer, Inc.
6.8. Sanofi-Aventis
6.9. Solvay Pharmaceuticals, Inc.
6.10. Teva Pharmaceutical Industries Ltd.

FIG. 1 Chemotherapy Induced Nausea and Vomiting Treatment Market: Research Methodology
FIG. 2 Chemotherapy Induced Nausea and Vomiting Treatment: Market Segmentation
FIG. 3 Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2017 (US$ Mn)
FIG. 4 Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2017
FIG. 6 Competitive Analysis: Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Key Players, 2017
FIG. 7 Global Ondansetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 8 Global Granisetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 9 Global Dolasetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 10 Global Palonosetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 11 Global Aprepitant Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 12 Global Casopitant Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 13 Global Netupitant Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 14 Global Metoclopramide Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 15 Global Prochlorperazine Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 16 Global Lorazepam Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 17 Global Other Drug Class Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 18 U.S. Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 19 Canada Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 20 U.K. Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 21 Germany Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 22 Rest of Europe Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 23 China Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 24 Japan Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 25 Rest of Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 26 Brazil Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 27 Mexico Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 28 Rest of Latin America Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 29 GCC Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 30 Rest of Middle East and Africa Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)

TABLE 1 Global Chemotherapy Induced Nausea and Vomiting Treatment Market Portraiture
TABLE 2 Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Global Serotonin Receptor Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 4 Global Neurokinin NK1 Receptor Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 5 Global Dopamine Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 6 Global Benzodiazepine Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 7 Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 8 North America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 9 North America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 10 Europe Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 11 Europe Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country/Region, 2015 – 2025 (US$ Mn)
TABLE 14 Latin America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 16 Middle East and Africa Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East and Africa Chemotherapy Induced Nausea and Vomiting Treatment Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 18 Baxter Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Eisai, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Helsinn Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 GlaxoSmithkline, Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 ProStrakan, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Sanofi-Aventis: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Solvay Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients